References
- BeanRHThe treatment of chronic ulcerative colitis with 6-mercaptopurineMed J Aust196249259259313969929
- Van DeventerSJTumour necrosis factor and Crohn’s diseaseGut1997404434489176068
- RutgeertsPVermeireSvan AsscheGBiological therapies for inflammatory bowel diseasesGastroenterology20091361182119719249397
- GrimmMCNew and emerging therapies for inflammatory bowel diseasesJ Gastroenterol Hepatol200924Suppl 3S69S7419799702
- AtreyaRNeurathMFNew therapeutic strategies for treatment of inflammatory bowel diseaseMucosal Immunol2008117518219079177
- RoglerGMichettiPKrugerFActive therapeutic immunization against TNF with a TNF-kinoid in Crohn’s disease patients: a Phase 1–2 studyGastroenterology2010138Suppl 1517
- EngelMANeurathMFNew pathophysiological insights and modern treatment of IBDJ Gastroenterol20104557158320213337
- ItoHTakazoeMFukudaYA pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active crohn’s diseaseGastroenterol20041264989996
- BeckerCFantiniMCSchrammCTGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signallingImmunity20042149150115485627
- GrivennikovSKarinETerzicJIL-6 and stat3 are required for survival of intestinal epithelial cells and development of colitis associated cancerCancer Cell20091510311319185845
- LyakhLTrinchieriGProvezzaLRegulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humansImmunol Rev200822611213119161420
- NeurathMFFussIKelsallBLAntibodies to interleukin 12 abrogate established experimental colitis in miceJ Exp Med1995182128112907595199
- DavidsonNJHudakSALesleyREIL-12, but not IFN-γ, plays a major role in sustaining the chronic phase of colitis in IL-10 deficient miceJ Immunol1998161314331499743382
- HueSAhernPBuonocoreSInterleukin-23 drives innate and T cell mediated intestinal inflammationJ Exp Med20062032473248317030949
- SandbornWJFeaganBJFedorakRNUstekinumab Crohn’s Disease Study Group. A randomised trial of ustekinumab, a human interleukin-12/23 monoclonal antibody in patients with moderate to severe Crohn’s diseaseGastroenterology20081351130114118706417
- PanaccioneRSandbornWGordonGBriakinumab (ABT874) for treatment of Crohn’s diseaseGut201059Suppl 3A11
- WaldnerMJNeurathMFNovel cytokine-targeted therapies and intestinal inflammationCurr opin Pharm20099702707
- DaneseSAngelucciEMalesciACaprilliRBiological agents for ulcerative colitis: hypes and hopesMed Res Rev200828220121817464967
- ReinischWHommesDWvan AsscheGA dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s diseaseGut2006551138114416492717
- Van AsscheGDalleINomanMA pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitisAm J Gastroenterol20039836937612591057
- BraatHRottiersPHommesDWA Phase I trial with transgenic bacteria expressing IL-10 in Crohn’s diseaseClin Gastroenterol Hepatol2006475475916716759
- TilgHVogelsangHLudwiczekOA randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitisGut2003521728173314633951
- Pena-RossiCSchreiberSGolubovicGClinical trial: a multicentre, randomised, double blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitisAiliment Pharmacol Ther200828758767
- SiegmundBTargeted therapies in inflammatory bowel diseaseDig Dis20092746546919897961
- SolerDChapmanTYangLWyantTEganRFedykERThe binding specificity and selective antagonism of vedolizumab, an anti-α4β7 integrin therapeutic antibody in development for inflammatory bowel diseasesJ Pharmacol Exp Therap2009330386487519509315
- HesterbergPEWinsor-HinesDBriskinMJRapid resolution of chronic colitis in the cotton-top tamarin with an antibody to the gut-homing integrin alpha 4 beta 7Gastroenterology1996111137313808898653
- PicarellaDHurlbutPRottmanJShiXButcherERinglerDJMonoclonal antibodies specific beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cellsJ Immunol1997158209921069036954
- LobbRRHelmerMEThe pathophysiologic role of alpha 4 integrins in vivoJ Clin Invest1994172217287525645
- Kleinschmidt-DeMastersBKTylerKLProgressive multifocal leucoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosisN Eng J Med2005353369374
- Van AsscheGvan RanstMSciotRProgressive multifocal leucoencephalopathy after natalizumab therapy for Crohn’s diseaseN Eng J Med2005353362368
- ButcherECWilliamsMYoungmanKRottLBriskinMLymphocyte trafficking and regional immunityAdv Immunol19997220925310361577
- SalmiMJalkanenSLymphocyte homing to the gut; attraction, adhesion and commitmentImmunol Rev200520610011316048544
- FeaganBGGreenbergGRWildGtreatment of ulcerative colitis with a humanised antibody to the alpha4beta7 integrinN Eng J Med200535224992507
- FeaganBGGreenbergGRWildGTreatment of active Crohn’s disease with MLN0002, a humanised antibody to the alpha4-beta7 integrinClin Gastroenterol Hepatol200861370137718829392
- EksteenBAdamsDHGSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn’s diseaseIDrugs201013747278120582872
- StronkhorstARademaSYongSLCD4 antibody treatment in patients with active Crohn’s disease: a phase I dose finding studyGut1997403203279135519
- MayerLEvolving paradigms in the pathogenesis of IBDJ Gastroenterol20104591619960355
- Van AsscheGSandbornWJFeaganBGDaclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialGut2006551568157416603634
- HanauerSSandbornWSandsBEA randomized placebo-controlled trial of Abatacept for moderately-to-severely active Crohn’s diseaseGastroenterology2010138Supp 186
- GoetzMAtreyaRGhalibafianMGallePRNeurathMFExacerbation of Ulcerative colitis following Rituximab salvage therapyInflamm Bowel Dis200713111365136817604367
- SchrezenmeirJde VresesMProbiotics, prebiotics and synbiotics-approaching a definitionAm J Clin Nutr200173361S364S11157342
- SartorRBTherapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, prebiotics and probioticsGastroenterology20041261620163315168372
- RoberfroidMPrebiotics: the concept revisitedJ Nutr2007137830S837S17311983
- KleessenBHartmannLBlautMOligofructose and long chain inulin: influence on the gut microbial ecology of rats associated with a human faecal floraBr J Nutr20018629130011502244
- SantosASanMMDiazDMPrebiotics and their long term influence on the microbial populations of the mouse bowelFood Microbiol20062349850316943043
- GibsonGRBeattyERWangXSelective stimulation of bifidobacteria in the human colon by oligofructose and inulinGastroenterology19951089759827698613
- CampbellJMFaheyGCJrWolfBWSelected indigestible oligosaccharides affect large bowel mass, caecal and faecal short chain fatty acids, pH and microflora in ratsJ Nutr19971271301369040556
- WongJMde SouzaRKendallCWEmamAJenkinsDJColonic health: fermentation and short chain fatty acidsJ Clin Gastroenterol20064023524316633129
- GionchettiPRizzelloFHelwigUProphylaxis of pouchitis onset with probiotic therapy: a double blind, placebo controlled trialGastroenterology20031241202120912730861
- MimuraTRizzelloFHelwigUOnce daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitisGut20045310811414684584
- QuigleyEMMPrebiotics and probiotics; modifying and mining the microbiotaPharm Res201061213218
- AndersonREOlaisonGTyskCAppendectomy and protection against ulcerative colitisN Eng J Med2001344808814
- DerbyLEJickHAppendectomy protects against ulcerative colitisEpidemiology199892052079504292
- CalkinsBMA meta-analysis of the role of smoking in inflammatory bowel diseaseDig Dis Sci198934184118542598752
- SonnenbergAMcCartyDJJacobsenSJGeographic variation of inflammatory bowel disease within the united statesGastroenterology19911001431491983816
- ShivanandaSLennard-JonesJLoganRIncidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative study on inflammatory bowel disease (EC-IBD)Gut1996396906979014768
- WeinstockJVElliottDEHelminths and the IBD hygiene hypothesisInflamm Bowel Dis20091512813318680198
- KhanWIBlennerhassetPAVargheseAKIntestinal nematode infection ameliorates experimental colitis in miceInfect Immun2002705931593712379667
- MoreelsTGNieuwendijkRJde ManJGConcurrent infection with schistosoma mansoni attenuates inflammation induced changes in colonic morphology, cytokine levels and smooth muscle contractility of trinitrobenzene sulphonic acid induced colitis in ratsGut2004539910714684583
- SummersRWElliotDEUrbanJFJrTrichuris suis therapy in Crohn’s diseaseGut200554879015591509
- SummersRWElliotDEUrbanJFJrTrichuris suis therapy for active ulcerative colitis: a randomised controlled trialGastroenterology200512882583215825065
- MitsuyamaKSataMTherapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of actionEx Cytotherapy2009112229237
- ArseneauKOCominelliFLeukocytapheresis in ulcerative colitis: a possible alternative to biological therapy?Dig Liver Dis20094155155219540820
- SandsBESandbornWJFeaganBA randomized, double-blind, sham controlled study of granulocyte/monocyte apheresis for active ulcerative colitisGastroenterology200813540040918602921
- GodoiDFCardosoCRFerrazDBHemopoietic SCT modulates gut inflammation in experimental inflammatory bowel diseaseBone Marrow Trans2010110
- OyamaYCraigRMTraynorAEAutologous hematopoietic stem cell transplantation in patients with refractory Crohn’s diseaseGastroenterology2005128355256315765390
- PranteraCLochsHGionchettiPRifaximin-EIR 400 mg tablets in the treatment of moderately active Crohn’s disease: results of the International, multicentre, randomized, double-blind, placebo-controlled trial RETIC-03Gut201059Suppl 3A1